A A A
Feed icon

News

chromosome 22q deletion

Parkinson's chromosome deletion linked to other genetic disorders

Researchers, led by BRC-supported Professor Nicholas Wood, UCL Institute of Neurology, have made a breakthrough in their understanding of Parkinson’s disease after they discovered a chromosome deletion linked to Parkinson’s disease and other genetic disorders. More...

Prof John Hardy

Prof John Hardy is the first UK winner of $3m Breakthrough Prize in Life Sciences

Professor John Hardy (UCL Institute of Neurology) has been awarded the $3 million Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimer’s disease, other forms of dementia and Parkinson’s disease. More...

John Hardy, PhD, right, accepted the 2015 Robert A. Pritzker Prize from MJFF VP Brian Fiske, PhD, and Michael J. Fox on April 15.

John Hardy awarded 2015 Robert A. Pritzker Prize for Leadership in Parkinson's Research

One of the UK Parkinson's Disease Consortium Principal Investigators, Prof John Hardy, has been awarded the 2015 Robert A. Pritzker Prize for his leadership in Parkinson's genetics research. The award was presented by Michael J. Fox at a ceremony in New York on April 15. From the Michael J. Fox Foundation website: More...

Webcast - Prof Nicholas Wood - Advances in Genetic Understanding of Parkinson's Disease.

Video: Advances in Genetic Understanding of Parkinson's Disease

Webcast of the presentation entitled ‘Advances in Genetic Understanding of Parkinson's Disease’ given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson’s Disease and Beyond, held in December 2014. More...

Pedigrees and I-FP-CIT SPECT scan images of the four families with GCH1 mutations involved in this study.

GCH1 gene and Parkinson's risk

A study published in Brain, led by researchers at UCL Institute of Neurology, has shown that genetic mutations which cause a decrease in dopamine production in the brain and lead to a form of childhood-onset Dystonia, also play a role in the development of Parkinson’s disease.
More...

Anthony Schapira

(Principal Investigator)

Tony Schapira


Prof Tony Schapira is the Head of the Department of Clinical Neuroscience at the UCL Institute of Neurology and Chairman of Clinical Neurosciences Specialties.

The primary area of research in the department is the investigation of the aetiology and pathogenesis of neurodegenerative disorders. Specifically the department has an interest in the genetics and biochemistry of Parkinson's disease, Huntington's disease and Friedreich's ataxia. The department has established an international reputation in this area and in the area of diseases of the mitochondrial respiratory chain and inborn errors of mitochondrial function. There are also extensive research programmes on the genetics and pathogenesis of dystonia, motor neurone disease and peripheral nerve disorders. A joint appointment with the Hammersmith Hospital has provided an additional research interest in neuropsychology. Facilities for research are extensive. There are general laboratories for biochemistry, molecular biology, tissue preparation etc, in addition to specialist laboratory space for tissue culture (4 hoods), molecular biology, radioactive work, fluorimetry, spectrophotometry, lipid chemistry and histochemistry. There are advanced facilities for image analysis including an electron microscope.

esearcherID


Contact details

Lab website


Link to Publications RSS button
Jump to: 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1981 | 1980 | 1977
Number of items: 683.

2016

Gegg, ME; Schapira, AH; (2016) Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiology of Disease , 90 pp. 43-50. 10.1016/j.nbd.2015.09.006. Green open access
file

Hong, CT; Chau, KY; Schapira, AH; (2016) The Cytomegalovirus protein pUL37×1 targets mitochondria to mediate neuroprotection. Scientific Reports , 6 , Article 31373. 10.1038/srep31373. Green open access
file

Hong, CT; Chau, KY; Schapira, AH; (2016) Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. Scientific Reports , 6 , Article 25344. 10.1038/srep25344. Green open access
file

Ivankovic, D; Chau, KY; Schapira, AH; Gegg, ME; (2016) Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. Journal of Neurochemistry , 136 (2) pp. 388-402. 10.1111/jnc.13412. Green open access
file

Kilpatrick, BS; Magalhaes, J; Beavan, MS; McNeill, A; Gegg, ME; Cleeter, MW; Bloor-Young, D; (2016) Endoplasmic reticulum and lysosomal Ca(2+) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts. Cell Calcium , 59 (1) pp. 12-20. 10.1016/j.ceca.2015.11.002. Green open access
file

Kilpatrick, BS; Yates, E; Grimm, C; Schapira, AH; Patel, S; (2016) Endo-lysosomal TRP mucolipin-1 channels trigger global ER Ca2+ release and Ca2+ influx. Journal of Cell Science , 129 (20) pp. 3859-3867. 10.1242/jcs.190322. Green open access
file

Lesage, S; Drouet, V; Majounie, E; Deramecourt, V; Jacoupy, M; Nicolas, A; Cormier-Dequaire, F; (2016) Loss of VPS1 3C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. AMERICAN JOURNAL OF HUMAN GENETICS , 98 (3) pp. 500-513. 10.1016/j.ajhg.2016.01.014.

Magalhaes, J; Gegg, ME; Migdalska-Richards, A; Doherty, MK; Whitfield, PD; Schapira, AH; (2016) Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Human Molecular Genetics 10.1093/hmg/ddw185. (In press). Green open access
file

Migdalska-Richards, A; Daly, L; Bezard, E; Schapira, AH; (2016) Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol , 80 (5) pp. 766-775. 10.1002/ana.24790.

Migdalska-Richards, A; Schapira, AH; (2016) The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem , 139 Su pp. 77-90. 10.1111/jnc.13385.

Pryde, KR; Smith, HL; Chau, KY; Schapira, AH; (2016) PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy. Journal of Cell Biology , 213 (2) pp. 163-171. 10.1083/jcb.201509003. Green open access
file

Ray Chaudhuri, K; Rojo, JM; Schapira, AH; Brooks, DJ; Stocchi, F; Odin, P; Antonini, A; (2016) Correction: A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS One , 11 (2) , Article e0150130. 10.1371/journal.pone.0150130.

Sanchez-Martinez, A; Beavan, M; Gegg, ME; Chau, K-Y; Whitworth, AJ; Schapira, AHV; (2016) Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. SCIENTIFIC REPORTS , 6 (ARTN 313) 10.1038/srep31380.

Scalco, RS; Gardiner, A; Desikan, M; Houlden, H; Hanna, MG; Schapira, A; Lachmann, R; (2016) Glycogen storage disease type XV: a case report. In: (Proceedings) 117th Meeting of the British-Neuropathological-Society. (pp. p. 50). WILEY-BLACKWELL

Scalco, RS; Gardiner, AR; Pitceathly, RDS; Hilton-Jones, D; Schapira, AH; Turner, C; Parton, M; (2016) CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: expanding the phenotypic spectrum of caveolinopathies. Neuromuscular Disorders , 26 (8) pp. 504-510. 10.1016/j.nmd.2016.05.006.

Schapira, AH; (2016) Advances in neurological research and practice. Eur J Neurol , 23 (12) pp. 1685-1693. 10.1111/ene.13214.

Schapira, AHV; Albanese, A; Brainin, M; Davie, C; Juvela, S; Leone, M; Meschia, J; (2016) Sirkka-Liisa Leinonen. EUROPEAN JOURNAL OF NEUROLOGY , 23 (4) pp. 673-674. 10.1111/ene.12697.

Schapira, AHV; Chiasserini, D; Beccari, T; Parnetti, L; (2016) Glucocerebrosidase in Parkinson's Disease: Insights Into Pathogenesis and Prospects for Treatment. MOVEMENT DISORDERS , 31 (6) pp. 830-835. 10.1002/mds.26616.

Toulorge, D; Schapira, AH; Hajj, R; (2016) Molecular changes in the postmortem parkinsonian brain. J Neurochem , 139 Su pp. 27-58. 10.1111/jnc.13696.

2015

Beavan, M; McNeill, A; Proukakis, C; Hughes, DA; Mehta, A; Schapira, AH; (2015) Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol , 72 (2) 201 - 208. 10.1001/jamaneurol.2014.2950. Green open access
file

Beavan, M; Schapira, AH; (2015) Glucocerebrosidase Gene Mutation and Preclinical Markers of Parkinson Disease - Reply. JAMA Neurology , 72 (6) , Article 724. 10.1001/jamaneurol.2015.0484. Green open access
file

Beavan, MS; (2015) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Doctoral thesis, UCL (University College London). Green open access
file

Booth, TC; Nathan, M; Waldman, AD; Quigley, A-M; Schapira, AH; Buscombe, J; (2015) The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1. AMERICAN JOURNAL OF NEURORADIOLOGY , 36 (2) pp. 229-235. 10.3174/ajnr.A3970.

Booth, TC; Nathan, M; Waldman, AD; Quigley, A-M; Schapira, AH; Buscombe, J; (2015) The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2. AMERICAN JOURNAL OF NEURORADIOLOGY , 36 (2) pp. 236-244. 10.3174/ajnr.A3971.

Chaudhuri, KR; Sauerbier, A; Rojo, JM; Sethi, K; Schapira, AHV; Brown, RG; Antonini, A; (2015) The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. PARKINSONISM & RELATED DISORDERS , 21 (3) pp. 287-291. 10.1016/j.parkreldis.2014.12.031.

Cornelis, MC; Byrne, EM; Esko, T; Nalls, MA; Ganna, A; Paynter, N; Monda, KL; (2015) Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. MOLECULAR PSYCHIATRY , 20 (5) pp. 647-656. 10.1038/mp.2014.107.

DeSouza, RM; Akram, H; Low, HL; Green, AL; Ashkan, K; Schapira, HV; (2015) The timing of deep brain stimulation for Parkinson disease in the UK from 1997 to 2012. EUROPEAN JOURNAL OF NEUROLOGY , 22 (10) 1417-COVER4. 10.1111/ene.12795.

Gardiner, A; Scalco, R; Pitceathly, R; Holton, J; Hanna, M; Schapira, A; Houlden, H; (2015) Glycogen storage disease type XV: A case report. In: (Proceedings) 20th International Congress of the World-Muscle-Society. (pp. S221-S221). PERGAMON-ELSEVIER SCIENCE LTD

Gegg, ME; Sweet, L; Wang, BH; Shihabuddin, LS; Sardi, SP; Schapira, AH; (2015) No evidence for substrate accumulation in Parkinson brains with GBA mutations. Movement Disorders , 30 (8) pp. 1085-1089. 10.1002/mds.26278. Green open access
file

Gkotsi, D; Lascaratos, G; Chau, D; Schapira, A; Garway-Heath, DF; (2015) Mitochondrial contribution to the resistance to glaucoma in ocular hypertension. In: (Proceedings) Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO). ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Hockey, LN; Kilpatrick, BS; Eden, E; Lin-Moshier, Y; Brailoiu, GC; Brailoiu, E; Futter, CE; (2015) Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by two-pore channel 2 inhibition. Journal of Cell Science , 128 pp. 232-238. 10.1242/​jcs.164152. Green open access
file

Keatinge, M; Bui, H; Menke, A; Chen, Y-C; Sokol, AM; Bai, Q; Ellett, F; (2015) Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. HUMAN MOLECULAR GENETICS , 24 (23) pp. 6640-6652. 10.1093/hmg/ddv369.

Kiely, AP; Ling, H; Asi, YT; Kara, E; Limousin, P; Lewis, P; Proukakis, C; (2015) Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. In: (Proceedings) 116th Meeting of the British-Neuropathological-Society. (pp. p. 31). WILEY-BLACKWELL

Kiely, AP; Ling, H; Asi, YT; Kara, E; Proukakis, C; Schapira, AH; Morris, HR; (2015) Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. In: BIOMED CENTRAL LTD

Kiely, AP; Ling, H; Asi, YT; Kara, E; Proukakis, C; Schapira, AH; Morris, HR; (2015) Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration , 10 , Article 41. 10.1186/s13024-015-0038-3. Green open access
file

Lascaratos, G; Chau, K-Y; Zhu, H; Gkotsi, D; King, R; Gout, I; Kamal, D; (2015) Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency. NEUROBIOLOGY OF DISEASE , 82 pp. 78-85. 10.1016/j.nbd.2015.05.012.

Leone, MA; Keindl, M; Schapira, AH; Deuschl, G; Federico, A; (2015) Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces. EUROPEAN JOURNAL OF NEUROLOGY , 22 (12) pp. 1505-1510. 10.1111/ene.12818.

Löhle, M; Hughes, D; Milligan, A; Richfield, L; Reichmann, H; Mehta, A; Schapira, AH; (2015) Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology , 84 (14) 1454 - 1464. 10.1212/WNL.0000000000001450. Green open access
file

Mullin, S; Schapira, A; (2015) The genetics of Parkinson's disease. BRITISH MEDICAL BULLETIN , 114 (1) pp. 39-52. 10.1093/bmb/ldv022.

Mullin, S; Schapira, AHV; (2015) Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease. NEUROLOGIC CLINICS , 33 (1) 1-+. 10.1016/j.ncl.2014.09.010.

Nalls, MA; Bras, J; Hernandez, DG; Keller, MF; Majounie, E; Renton, AE; Saad, M; (2015) NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging , 36 (3) 1605.e7-1605.12. 10.1016/j.neurobiolaging.2014.07.028.

Porcari, R; Proukakis, C; Waudby, CA; Bolognesi, B; Mangione, PP; Paton, JF; Mullin, S; (2015) The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein. J Biol Chem , 290 (4) 2395 - 2404. 10.1074/jbc.M114.610527. Green open access
file

Scalco, R; Gardiner, A; Pitceathly, R; Turner, C; Parton, M; Fialho, D; Hanna, M; (2015) Caveolinopathy presenting with muscle pain and rhabdomyolysis. In: (Proceedings) 20th International Congress of the World-Muscle-Society. (pp. S297-S297). PERGAMON-ELSEVIER SCIENCE LTD

Schapira, AHV; (2015) Neurology in evolution 2014-2015. EUROPEAN JOURNAL OF NEUROLOGY , 22 (12) pp. 1493-1502. 10.1111/ene.12918.

Schapira, AHV; (2015) Glucocerebrosidase and Parkinson disease: Recent advances. MOLECULAR AND CELLULAR NEUROSCIENCE , 66 pp. 37-42. 10.1016/j.mcn.2015.03.013.

Schapira, AHV; (2015) The measurement and importance of non-motor symptoms in Parkinson disease. EUROPEAN JOURNAL OF NEUROLOGY , 22 (1) pp. 2-3. 10.1111/ene.12523.

Tofaris, GK; Schapira, AHV; (2015) Neurodegenerative diseases in the era of targeted therapeutics: how to handle a tangled issue. MOLECULAR AND CELLULAR NEUROSCIENCE , 66 pp. 1-2. 10.1016/j.mcn.2015.03.002.

2014

Beilina, A; Rudenko, IN; Kaganovich, A; Civiero, L; Chau, H; Kalia, SK; Kalia, LV; (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A , 111 (7) pp. 2626-2631. 10.1073/pnas.1318306111.

Cooper, JM; Wiklander, PB; Nordin, JZ; Al-Shawi, R; Wood, MJ; Vithlani, M; Schapira, AH; (2014) Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord , 29 (12) 1476 - 1485. 10.1002/mds.25978. Green open access
file

Dong, J; Gao, J; Nalls, M; Gao, X; Huang, X; Han, J; Singleton, AB; (2014) Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiol Aging , 35 (6) 1512.e5-1512.10. 10.1016/j.neurobiolaging.2013.12.020.

Gkotsi, D; Begum, R; Salt, T; Lascaratos, G; Hogg, C; Chau, KY; Schapira, AH; (2014) Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Exp Eye Res , 122 pp. 50-53. 10.1016/j.exer.2014.02.023. Green open access
file

Gómez-Sánchez, R; Gegg, ME; Bravo-San Pedro, JM; Niso-Santano, M; Alvarez-Erviti, L; Pizarro-Estrella, E; Gutiérrez-Martín, Y; (2014) Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiol Dis , 62 426-440. 10.1016/j.nbd.2013.10.021. Green open access
file

Hauser, RA; Gordon, MF; Mizuno, Y; Poewe, W; Barone, P; Schapira, AH; Rascol, O; (2014) Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. PARKINSONS DISEASE (ARTN 467) 10.1155/2014/467131.

Hauser, RA; Schapira, AHV; Barone, P; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2014) Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. EUROPEAN JOURNAL OF NEUROLOGY , 21 (5) pp. 736-743. 10.1111/ene.12375.

Kiely, AP; Asi, YT; Kara, E; Limousin, P; Ling, H; Lewis, P; Proukakis, C; (2014) How do G51D SNCA mutation cases compare clinically and neuropathologically to SNCA duplication and H50Q SNCA mutation? In: (Proceedings) 115th Meeting of the British-Neuropathological-Society, Institute-of-Child-Health. (pp. pp. 11-12). WILEY-BLACKWELL

Loehle, M; Ramberg, C-J; Reichmann, H; Schapira, AHV; (2014) Early Versus Delayed Initiation of Pharmacotherapy in Parkinson's Disease. DRUGS , 74 (6) pp. 645-657. 10.1007/s40265-014-0209-5.

Marin, C; Bonastre, M; Mengod, G; Cortes, R; Giralt, A; Obeso, JA; Schapira, AH; (2014) Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. NEUROBIOLOGY OF DISEASE , 64 pp. 36-47. 10.1016/j.nbd.2013.12.009.

McNeill, A; Magalhaes, J; Shen, C; Chau, KY; Hughes, D; Mehta, A; Foltynie, T; (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain , 137 (5) pp. 1481-1495. 10.1093/brain/awu020. Green open access
file

McNeill, A; Roberti, G; Lascaratos, G; Hughes, D; Mehta, A; Garway-Heath, DF; Schapira, AHV; (2014) Corrigendum to "Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study" [Mol. Genet. Metab. 109 (2013) 221-223]. Molecular Genetics and Metabolism , 111 (3) 408-. 10.1016/j.ymgme.2013.12.297.

McNeill, A; Roberti, G; Lascaratos, G; Hughes, D; Mehta, A; Garway-Heath, DF; Schapira, AHV; (2014) Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study (vol 109, pg 221, 2013). MOLECULAR GENETICS AND METABOLISM , 111 (3) p. 408. 10.1016/j.ymgme.2013.12.297.

Nalls, MA; Pankratz, N; Lill, CM; Do, CB; Hernandez, DG; Saad, M; DeStefano, AL; (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. NATURE GENETICS , 46 (9) 989-+. 10.1038/ng.3043.

Nalls, MA; Saad, M; Noyce, AJ; Keller, MF; Schrag, A; Bestwick, JP; Traynor, BJ; (2014) Genetic comorbidities in Parkinson's disease. HUMAN MOLECULAR GENETICS , 23 (3) pp. 831-841. 10.1093/hmg/ddt465.

Proukakis, C; Shoaee, M; Morris, J; Brier, T; Kara, E; Sheerin, UM; Charlesworth, G; (2014) Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations. Mov Disord , 29 (8) 060-1064. 10.1002/mds.25883. Green open access
file

Proukakis, C; Shoaee, M; Morris, J; Brier, T; Kara, E; Sheerin, UM; Charlesworth, G; (2014) Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations. Movement Disorders , 29 (8) pp. 1060-1064. 10.1002/mds.25883.

Schapira, AHV; (2014) Recent advances in neurology 2013-2014. EUROPEAN JOURNAL OF NEUROLOGY , 21 (12) pp. 1425-1434. 10.1111/ene.12619.

Schapira, AHV; Olanow, CW; Greenamyre, JT; Bezard, E; (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. LANCET , 384 (9942) pp. 545-555. 10.1016/S0140-6736(14)61010-2.

Schapira, AHV; Patel, S; (2014) Targeting Mitochondria for Neuroprotection in Parkinson Disease. JAMA NEUROLOGY , 71 (5) pp. 537-538. 10.1001/jamaneurol.2014.64.

Zokaei, N; McNeill, A; Proukakis, C; Beavan, M; Jarman, P; Korlipara, P; Hughes, D; (2014) Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. BRAIN , 137 pp. 2303-2311. 10.1093/brain/awu143.

2013

Alvarez-Erviti, L; Seow, Y; Schapira, AHV; Rodriguez-Oroz, MC; Obeso, JA; Cooper, JM; (2013) Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease. CELL DEATH & DISEASE , 4 (ARTN e54) 10.1038/cddis.2013.73. Gold open access

Batla, A; Stamelou, M; Mencacci, N; Schapira, AH; Bhatia, KP; (2013) Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease. Mov Disord , 28 (8) 1159 - 1160. 10.1002/mds.25318. Green open access
file

Beavan, MS; Schapira, AHV; (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. ANNALS OF MEDICINE , 45 (8) pp. 511-521. 10.3109/07853890.2013.849003.

Berg, D; Lang, AE; Postuma, RB; Maetzler, W; Deuschl, G; Gasser, T; Siderowf, A; (2013) Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. LANCET NEUROLOGY , 12 (5) pp. 514-524. 10.1016/S1474-4422(13)70047-4.

Chau, KY; Cooper, JM; Schapira, AH; (2013) Pramipexole reduces phosphorylation of α-Synuclein at Serine-129. Journal of Molecular Neuroscience , 51 pp. 573-580. 10.1007/s12031-013-0030-8. Green open access
filefilefilefilefilefile

Cleeter, MWJ; Chau, K-Y; Gluck, C; Mehta, A; Hughes, DA; Duchen, M; Wood, NW; (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. NEUROCHEMISTRY INTERNATIONAL , 62 (1) pp. 1-7. 10.1016/j.neuint.2012.10.010. Gold open access

Duran, R; Mencacci, NE; Angeli, AV; Shoai, M; Deas, E; Houlden, H; Mehta, A; (2013) The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders , 28 (2) 232 - 236. 10.1002/mds.25248. Green open access
file

Ferreira, JJ; Katzenschlager, R; Bloem, BR; Bonuccelli, U; Burn, D; Deuschl, G; Dietrichs, E; (2013) Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. EUROPEAN JOURNAL OF NEUROLOGY , 20 (1) 5-+. 10.1111/j.1468-1331.2012.03866.x.

Gegg, ME; Cooper, JM; Chau, K-Y; Rojo, M; Schapira, AHV; Taanman, J-W; (2013) Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy (vol 19, pg 4861, 2010). HUMAN MOLECULAR GENETICS , 22 (8) p. 1697. 10.1093/hmg/ddt046.

Holmans, P; Moskvina, V; Jones, L; Sharma, M; Vedernikov, A; Buchel, F; Sadd, M; (2013) A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinsons disease. HUMAN MOLECULAR GENETICS , 22 (5) pp. 1039-1049. 10.1093/hmg/dds492.

Kilpatrick, BS; Eden, ER; Schapira, AH; Futter, CE; Patel, S; (2013) Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. JOURNAL OF CELL SCIENCE , 126 (1) pp. 60-66. 10.1242/jcs.118836.

Klebe, S; Golmard, JL; Nalls, MA; Saad, M; Singleton, AB; Bras, JM; Hardy, J; (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. Journal of Neurology, Neurosurgery and Psychiatry , 84 (6) 666 - 673. 10.1136/jnnp-2012-304475. Green open access
file

Manzoni, C; Mamais, A; Dihanich, S; McGoldrick, P; Devine, MJ; Zerle, J; Kara, E; (2013) Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochemical and Biophysical Research Communications , 441 (4) pp. 862-866. 10.1016/j.bbrc.2013.10.159. Green open access
file

McNeill, A; Healy, DG; Schapiro, AHV; Taanman, J-W; (2013) Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations. MOLECULAR GENETICS AND METABOLISM , 109 (4) pp. 402-403. 10.1016/j.ymgme.2013.06.002.

McNeill, A; Roberti, G; Lascaratos, G; Hughes, D; Mehta, A; Garway-Heath, DF; Schapira, AH; (2013) Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. Molecular Genetics and Metabolism , 109 (2) 221 - 223. 10.1016/j.ymgme.2013.04.001. Green open access
file

McNeill, A; Wu, RM; Tzen, KY; Aguiar, PC; Arbelo, JM; Barone, P; Bhatia, K; (2013) Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLOS ONE , 8 (7) , Article e69190. 10.1371/journal.pone.0069190. Green open access
file

Mullin, S; Schapira, A; (2013) α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Molecular neurobiology , 47 (2) pp. 587-597.

Mullin, S; Schapira, A; (2013) alpha-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease. MOLECULAR NEUROBIOLOGY , 47 (2) pp. 587-597. 10.1007/s12035-013-8394-x.

Olanow, CW; Kieburtz, K; Rascol, O; Poewe, W; Schapira, AH; Emre, M; Nissinen, H; (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. MOVEMENT DISORDERS , 28 (8) pp. 1064-1071. 10.1002/mds.25364.

Olanow, CW; Schapira, AHV; (2013) Therapeutic Prospects for Parkinson Disease. ANNALS OF NEUROLOGY , 74 (3) pp. 337-347. 10.1002/ana.24011.

Osellame, LD; Rahim, AA; Hargreaves, IP; Gegg, ME; Richard-Londt, A; Brandner, S; Waddington, SN; (2013) Mitochondria and quality control defects in a mouse model of Gaucher Disease-links to Parkinson's Disease. Cell Metabolism , 17 (6) pp. 941-953. 10.1016/j.cmet.2013.04.014. Green open access
filefile

Pichler, I; Del Greco, MF; Gogele, M; Lill, CM; Bertram, L; Do, CB; Eriksson, N; (2013) Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS.Med. , 10 (6) , Article e1001462. 10.1371/journal.pmed.1001462. Green open access
file

Proukakis, C; Dudzik, CG; Brier, T; MacKay, DS; Cooper, JM; Millhauser, GL; Houlden, H; (2013) A NOVEL alpha-SYNUCLEIN MISSENSE MUTATION IN PARKINSON DISEASE. NEUROLOGY , 80 (11) pp. 1062-1064.

Proukakis, C; Houlden, H; Schapira, AH; (2013) Somatic alpha-synuclein mutations in Parkinson's disease: Hypothesis and preliminary data. Movement Disorders , 28 (6) pp. 705-712. 10.1002/mds.25502.

Proukakis, C; Houlden, H; Schapira, AH; (2013) Somatic alpha-synuclein mutations in Parkinson's disease: Hypothesis and preliminary data. Movement Disorders 10.1002/mds.25502. Green open access
file

Ray Chaudhuri, K; Rojo, JM; Schapira, AH; Brooks, DJ; Stocchi, F; Odin, P; Antonini, A; (2013) A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One , 8 (2) , Article e57221. 10.1371/journal.pone.0057221. Green open access
file

Sarkozy, A; Hicks, D; Hudson, J; Laval, SH; Barresi, R; Hilton-Jones, D; Deschauer, M; (2013) ANO5 Gene Analysis in a Large Cohort of Patients with Anoctaminopathy: Confirmation of Male Prevalence and High Occurrence of the Common Exon 5 Gene Mutation. HUMAN MUTATION , 34 (8) pp. 1111-1118. 10.1002/humu.22342.

Sarkozy, A; Hicks, D; Hudson, J; Laval, SH; Barresi, R; Hilton-Jones, D; Deschauer, M; (2013) ANO5 Gene Analysis in a Large Cohort of Patients with Anoctaminopathy: Confirmation of Male Prevalence and High Occurrence of the Common Exon 5 Gene Mutation. Human Mutation , 34 (8) pp. 1111-1118. 10.1002/humu.22342.

Schapira, AH; (2013) Progress in European neurology 2012-2013. Eur J Neurol , 20 (12) pp. 1499-1507. 10.1111/ene.12303.

Schapira, AH; (2013) Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol , 26 (4) 395 - 400. 10.1097/WCO.0b013e3283633741. Green open access
file

Schapira, AHV; (2013) Calcium dysregulation in Parkinson's disease. BRAIN , 136 pp. 2015-2016. 10.1093/brain/awt180.

Schapira, AHV; (2013) Mitochondrial diseases. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , 43 1 - 1.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2013) Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. EUROPEAN JOURNAL OF NEUROLOGY , 20 (1) pp. 50-56. 10.1111/j.1468-1331.2012.03712.x.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2013) Success rate, efficacy, and safety/tolerability of overnight switching from immediate-to extended-release pramipexole in advanced Parkinson's disease. EUROPEAN JOURNAL OF NEUROLOGY , 20 (1) pp. 180-187. 10.1111/j.1468-1331.2012.03822.x.

Schapira, AHV; Gegg, ME; (2013) Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , 110 (9) pp. 3214-3215. 10.1073/pnas.1300822110.

Schapira, AHV; McDermott, MP; Barone, P; Comella, CL; Albrecht, S; Hsu, HH; Massey, DH; (2013) Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. LANCET NEUROLOGY , 12 (8) pp. 747-755. 10.1016/S1474-4422(13)70117-0.

Schapira, AHV; Stocchi, F; Borgohain, R; Onofrj, M; Bhatt, M; Lorenzana, P; Lucini, V; (2013) Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. EUROPEAN JOURNAL OF NEUROLOGY , 20 (2) pp. 271-280. 10.1111/j.1468-1331.2012.03840.x.

deSouza, RM; Moro, E; Lang, AE; Schapira, AH; (2013) Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol , 73 (5) 565 - 575. 10.1002/ana.23890. Green open access
file

2012

Cnop, M; Igoillo-Esteve, M; Rai, M; Begu, A; Serroukh, Y; Depondt, C; Musuaya, AE; (2012) Central Role and Mechanisms of beta-Cell Dysfunction and Death in Friedreich Ataxia-Associated Diabetes. ANNALS OF NEUROLOGY , 72 (6) pp. 971-982. 10.1002/ana.23698.

Devine, MJ; Kaganovich, A; Ryten, M; Mamais, A; Trabzuni, D; Manzoni, C; McGoldrick, P; (2012) Correction: Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLOS ONE , 7 (1) , Article e22489. 10.1371/annotation/c12e4f9e-5aae-424b-a69f-fddf16976dc5. Green open access
file

Duran, R; McNeill, A; Mehta, A; Hughes, D; Cox, T; Deegan, P; Schapira, AHV; (2012) Novel pathogenic mutations in the glucocerebrosidase locus. MOLECULAR GENETICS AND METABOLISM , 106 (4) pp. 495-497. 10.1016/j.ymgme.2012.05.006. Gold open access

Duran, R; McNeill, A; Mehta, A; Hughes, D; Cox, T; Deegan, P; Schapira, AHV; (2012) Novel pathogenic mutations in the glucocerebrosidase locus. Molecular Genetics and Metabolism , 106 (4) pp. 495-497. 10.1016/j.ymgme.2012.05.006.

Gardiner, AR; Bhatia, KP; Stamelou, M; Dale, RC; Kurian, MA; Schneider, SA; Wali, GM; (2012) PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology , 79 (21) pp. 2115-2121. 10.1212/WNL.0b013e3182752c5a.

Gegg, ME; Burke, D; Heales, SJR; Cooper, JM; Hardy, J; Wood, NW; Schapira, AHV; (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. ANNALS OF NEUROLOGY , 72 (3) pp. 455-463. 10.1002/ana.23614.

Keller, MF; Saad, M; Bras, J; Bettella, F; Nicolaou, N; Simon-Sanchez, J; Mittag, F; (2012) Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. HUMAN MOLECULAR GENETICS , 21 (22) pp. 4996-5009. 10.1093/hmg/dds335.

Klionsky, DJ; Abdalla, FC; Abeliovich, H; Abraham, RT; Acevedo-Arozena, A; Adeli, K; Agholme, L; (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. AUTOPHAGY , 8 (4) pp. 445-544. 10.4161/auto.19496.

Lascaratos, G; Garway-Heath, DF; Willoughby, CE; Chau, K-Y; Schapira, AHV; (2012) Mitochondrial dysfunction in glaucoma: Understanding genetic influences. MITOCHONDRION , 12 (2) pp. 202-212. 10.1016/j.mito.2011.11.004.

McNeill, A; Duran, R; Hughes, DA; Mehta, A; Schapira, AH; (2012) A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. [Letter]. Journal of Neurology, Neurosurgery & Psychiatry , 83 (8) 853 -854. 10.1136/jnnp-2012-302402. Green open access
file

McNeill, A; Duran, R; Proukakis, C; Bras, J; Hughes, D; Mehta, A; Hardy, J; (2012) Hyposmia and cognitive impairment in Gaucher disease patients and carriers. MOVEMENT DISORDERS , 27 (4) pp. 526-532. 10.1002/mds.24945.

McNeill, A; Hughes, D; Mehta, A; Schapira, A; (2012) Hyposmia and cognitive impairment in gaucher disease patients and carriers. In: (Proceedings) British Human Genetics Conference. (pp. S63-S63). BMJ PUBLISHING GROUP

Mittag, F; Buechel, F; Saad, M; Jahn, A; Schulte, C; Bochdanovits, Z; Simon-Sanchez, J; (2012) Use of support vector machines for disease risk prediction in genome-wide association studies: Concerns and opportunities. HUMAN MUTATION , 33 (12) pp. 1708-1718. 10.1002/humu.22161.

Mizuno, Y; Yamamoto, M; Kuno, S; Hasegawa, K; Hattori, N; Kagimura, T; Sarashina, A; (2012) Efficacy and Safety of Extended-Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease: A Double-Blind, Randomized Trial. CLINICAL NEUROPHARMACOLOGY , 35 (4) pp. 174-181. 10.1097/WNF.0b013e31825f77b9.

Osellame, LD; Rahim, A; Gegg, ME; Waddington, S; Schapira, AHV; Duchen, MR; (2012) Accumulation of damaged mitochondria in neuropathic Gaucher disease, the most prevalent risk factor for Parkinson's disease, is due to defective cellular degradation machinery. In: (pp. S79-S80). ELSEVIER SCIENCE BV

Papkovskaia, TD; Chau, K-Y; Inesta-Vaquera, F; Papkovsky, DB; Healy, DG; Nishio, K; Staddon, J; (2012) G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. HUMAN MOLECULAR GENETICS , 21 (19) pp. 4201-4213. 10.1093/hmg/dds244. Gold open access

Schapira, AH; (2012) Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal , 16 (9) pp. 965-973. 10.1089/ars.2011.4419.

Schapira, AH; Hillbom, M; (2012) Advances in neurology 2011-12. Eur J Neurol , 19 (10) pp. 1267-1275. 10.1111/j.1468-1331.2012.03870.x.

Schapira, AH; Tan, EK; (2012) Optimizing treatment for Parkinson's disease. Eur J Neurol , 19 (12) pp. 1483-1486. 10.1111/ene.12025.

Schapira, AHV; (2012) Mitochondrial diseases. LANCET , 379 (9828) pp. 1825-1834. 10.1016/S0140-6736(11)61305-6.

Stocchi, F; Borgohain, R; Onofrj, M; Schapira, AHV; Bhatt, M; Lucini, V; Giuliani, R; (2012) A Randomized, Double-Blind, Placebo-Controlled Trial of Safinamide as Add-on Therapy in Early Parkinson's Disease Patients. MOVEMENT DISORDERS , 27 (1) pp. 106-112. 10.1002/mds.23954.

Wray, S; Self, M; NINDS Parkinson's Disease iPSC Consortium, ; NINDS Huntington's Disease iPSC Consortium, ; NINDS ALS iPSC Consortium, ; Lewis, PA; Taanman, JW; (2012) Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLOS One , 7 (8) , Article e43099. 10.1371/journal.pone.0043099. Green open access
file

2011

Abramov, AY; Gegg, M; Grunewald, A; Wood, NW; Klein, C; Schapira, AHV; (2011) Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease. PLOS ONE , 6 (10) , Article e25622. 10.1371/journal.pone.0025622. Green open access
file

Alvarez-Erviti, L; Seow, Y; Schapira, AH; Gardiner, C; Sargent, IL; Wood, MJA; Cooper, JM; (2011) Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. NEUROBIOL DIS , 42 (3) 360 - 367. 10.1016/j.nbd.2011.01.029. Gold open access

Brainin, M; Berardelli, A; Boon, P; Gilhus, NE; Leys, D; Ludolph, A; Schapira, AHV; (2011) Comment from the EFNS Scientific Committee on the letter from Gunther Haag concerning Bendsten L et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17: 1318-1325. EUR J NEUROL , 18 (7) E83 - E84. 10.1111/j.1468-1331.2011.03382.x.

Devine, MJ; Kaganovich, A; Ryten, M; Mamais, A; Trabzuni, D; Manzoni, C; McGoldrick, P; (2011) Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLOS ONE , 6 (7) , Article e22489. 10.1371/journal.pone.0022489. Green open access
file

Devine, MJ; Ryten, M; Vodicka, P; Thomson, AJ; Burdon, T; Houlden, H; Cavaleri, F; (2011) Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. NAT COMMUN , 2 , Article 440. 10.1038/ncomms1453. Gold open access

Gegg, ME; Schapira, AHV; (2011) PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2 Implications for Parkinson disease pathogenesis. AUTOPHAGY , 7 (2) 243 - 245. 10.4161/auto.7.2.14332.

Meissner, WG; Frasier, M; Gasser, T; Goetz, CG; Lozano, A; Piccini, P; Obeso, JA; (2011) Priorities in Parkinson's disease research. NATURE REVIEWS DRUG DISCOVERY , 10 (5) pp. 377-393. 10.1038/nrd3430.

Plagnol, V; Nalls, MA; Bras, JM; Hernandez, DG; Sharma, M; Sheerin, UM; Saad, M; (2011) A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease. PLoS Genetics , 7 (6) , Article e1002142. 10.1371/journal.pgen.1002142. Green open access
file

Poewe, W; Rascol, O; Barone, P; Hauser, RA; Mizuno, Y; Haaksma, M; Salin, L; (2011) Extended-release pramipexole in early Parkinson disease A 33-week randomized controlled trial. NEUROLOGY , 77 (8) 759 - 766.

Schapira, AH; (2011) Mitochondrial pathology in Parkinson's disease. Mt Sinai J Med , 78 (6) pp. 872-881. 10.1002/msj.20303.

Schapira, AH; (2011) Aetiopathogenesis of Parkinson's disease. J Neurol , 258 (Suppl 2) S307-S310. 10.1007/s00415-011-6016-y.

Schapira, AH; Gegg, M; (2011) Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinson's Disease , 2011 , Article 159160. 10.4061/2011/159160. Green open access
file

Schapira, AH; Hillbom, M; (2011) Publishing changes and information delivery in the clinical neurosciences. Eur J Neurol , 18 (12) pp. 1365-1372. 10.1111/j.1468-1331.2011.03594.x.

Schapira, AH; Jenner, P; (2011) Etiology and Pathogenesis of Parkinson's Disease. MOVEMENT DISORD , 26 (6) 1049 - 1055. 10.1002/mds.23732.

Schapira, AHV; (2011) Challenges to the development of disease-modifying therapies in Parkinson's disease. EUR J NEUROL , 18 16 - 21. 10.1111/j.1468-1331.2010.03324.x.

Schapira, AHV; (2011) The management of Parkinson's disease - what is new? EUR J NEUROL , 18 1 - 2. 10.1111/j.1468-1331.2010.03323.x.

Schapira, AHV; (2011) Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease A Review of Symptomatic and Potential Disease-Modifying Effects. CNS DRUGS , 25 (12) pp. 1061-1071.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Salin, L; (2011) Extended-release pramipexole in advanced Parkinson disease A randomized controlled trial. NEUROLOGY , 77 (8) 767 - 774.

Schapira, AHV; Schrag, A; (2011) Parkinson disease clinical subtypes and their implications. NAT REV NEUROL , 7 (5) 247 - 248. 10.1038/nrneurol.2011.40.

Sivam, D; Rizos, A; Martin, A; Naidu, Y; Renton, T; Schapira, AHV; Martinez-Martin, P; (2011) Pain in Parkinson's disease: Observational study of 225 patients. In: MOVEMENT DISORDERS. (pp. S182 - S182).

Stocchi, F; Giorgi, L; Hunter, B; Schapira, AHV; (2011) PREPARED: Comparison of Prolonged and Immediate Release Ropinirole in Advanced Parkinson's Disease. MOVEMENT DISORD , 26 (7) 1259 - 1265. 10.1002/mds.23498.

Tan, EK; Schapira, AH; (2011) LRRK2 as a therapeutic target in Parkinson's disease. EUR J NEUROL , 18 (4) 545 - 546. 10.1111/j.1468-1331.2010.03305.x.

Tan, EK; Schapira, AH; (2011) New LRRK2 variants identified in Parkinson's disease. EUR J NEUROL , 18 (3) 369 - 370. 10.1111/j.1468-1331.2010.03163.x.

2010

Schapira, AH and Fahn, S and Lang, AET (Eds). (2010) Movement Disorders 4: Blue Book Neurology Series. [Book]. (Vol.34). Elsevier Health Sciences

Alvarez-Erviti, L; Rodriguez-Oroz, MC; Cooper, JM; Caballero, C; Ferrer, I; Obeso, JA; Schapira, AHV; (2010) Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. ARCH NEUROL-CHICAGO , 67 (12) 1464 - 1472. 10.1001/archneuro1.2010.198.

Chau, KY; Cooper, JM; Schapira, AHV; (2010) Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. NEUROCHEM INT , 57 (5) 525 - 529. 10.1016/j.neuint.2010.06.017.

Chaudhuri, KR; Prieto-Jurcynska, C; Naidu, Y; Mitra, T; Frades-Payo, B; Tluk, S; Ruessmann, A; (2010) The Nondeclaration of Nonmotor Symptoms of Parkinson's Disease to Health Care Professionals: An International Study Using the Nonmotor Symptoms Questionnaire. MOVEMENT DISORD , 25 (6) 704 - 709. 10.1002/mds.22868.

Gegg, ME; Cooper, JM; Chau, KY; Rojo, M; Schapira, AHV; Taanman, JW; (2010) Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. HUM MOL GENET , 19 (24) 4861 - 4870. 10.1093/hmg/ddq419.

Grunewald, A; Voges, L; Rakovic, A; Kasten, M; Kock, N; Schapira, AHV; Orolicki, S; (2010) Impact of Mutations in Parkin on Mitochondrial Function and Morphology. In: NEUROLOGY. (pp. A261 - A261). LIPPINCOTT WILLIAMS & WILKINS

Grunewald, A; Voges, L; Rakovic, A; Kasten, M; Vandebona, H; Hemmelmann, C; Lohmann, K; (2010) Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLOS ONE , 5 (9) , Article e12962. 10.1371/journal.pone.0012962. Green open access
file

Hauser, RA; Schapira, AHV; Rascol, O; Barone, P; Mizuno, Y; Salin, L; Haaksma, M; (2010) Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease. MOVEMENT DISORD , 25 (15) 2542 - 2549. 10.1002/mds.23317.

Kajihara, M; Montagnese, S; Khanna, P; Amodio, P; Schapira, AH; Dusheiko, GM; Morgan, MY; (2010) Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases. Eur.J.Gastroenterol.Hepatol. , 22 (5) pp. 628-631.

Kajihara, M; Montagnese, S; Khanna, P; Amodio, P; Schapira, AHV; Dusheiko, GM; Morgan, MY; (2010) Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha 2b: a report of two cases. EUR J GASTROEN HEPAT , 22 (5) 628 - 631. 10.1097/MEG.0b013e32833383e3.

Obeso, JA; Rodriguez-Oroz, MC; Goetz, CG; Marin, C; Kordower, JH; Rodriguez, M; Hirsch, EC; (2010) Missing pieces in the Parkinson's disease puzzle. NAT MED , 16 (6) 653 - 661.

Rajagopalan, B; Francis, JM; Cooke, F; Korlipara, LVP; Blamire, AM; Schapira, AHV; Madan, J; (2010) Analysis of the Factors Influencing the Cardiac Phenotype in Friedreich's Ataxia. MOVEMENT DISORD , 25 (7) 846 - 852. 10.1002/mds.22864.

Rascol, O; Barone, P; Hauser, RA; Mizuno, Y; Poewe, W; Schapira, AHV; Salin, L; (2010) Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease. MOVEMENT DISORD , 25 (14) 2326 - 2332. 10.1002/mds.23262.

ScHapira, AHV; Samuels, MA; (2010) SERIES PREFACE. (Vol.35).

Schapira, A; (2010) Parkinson's Disease in Daily Practice. [Book]. John Wiley & Sons Inc

Schapira, AHV; (2010) Safinamide in the treatment of Parkinson's disease. EXPERT OPIN PHARMACO , 11 (13) 2261 - 2268. 10.1517/14656566.2010.511612.

Schapira, AHV; (2010) Complex I: Inhibitors, inhibition and neurodegeneration. EXP NEUROL , 224 (2) 331 - 335. 10.1016/j.expneurol.2010.03.028.

Schapira, AHV; (2010) Movement disorders: advances in cause and treatment. LANCET NEUROL , 9 (1) 6 - 7.

Schapira, AHV; (2010) Future Strategies for Neuroprotection in Parkinson's Disease. NEURODEGENER DIS , 7 (1-3) 210 - 212. 10.1159/000295666.

Schapira, AHV; Albrecht, S; Barone, P; Comella, CL; McDermott, MP; Mizuno, Y; Poewe, W; (2010) Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study. MOVEMENT DISORD , 25 (11) 1627 - 1632. 10.1002/mds.23143.

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2010) Comparisons among responses to pramipexole extended-release as adjunctive treatment in Japanese and non-Japanese studies of advanced Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 374 - 374). WILEY-BLACKWELL

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Debieuvre, C; (2010) Sustained off-time decrease in patients using pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 100 - 100). WILEY-BLACKWELL

Schapira, AHV; Barone, P; Hauser, RA; Mizuno, Y; Rascol, O; Busse, M; Salin, L; (2010) Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S309 - S309). WILEY-LISS

Schapira, AHV; Fox, S; Hauser, R; Jankovic, J; Kulisevsky, J; Pahwa, R; Poewe, W; (2010) SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S308 - S309). WILEY-LISS

Schapira, AHV; Samuels, MA; (2010) Series preface. (Vol.36).

Schapira, AHV; Samuels, MA; (2010) SERIES PREFACE. (Vol.34).

Schapira, AHV; Tolosa, E; (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. NAT REV NEUROL , 6 (6) 309 - 317. 10.1038/nrneurol.2010.52.

Tan, EK; Schapira, AH; (2010) Summary of GIGYF2 studies in Parkinson's disease: the burden of proof. EUR J NEUROL , 17 (2) 175 - 176. 10.1111/j.1468-1331.2009.02834.x.

Turner, C; Schapira, AHV; (2010) Mitochondrial matters of the brain: the role in Huntington's disease. J BIOENERG BIOMEMBR , 42 (3) 193 - 198. 10.1007/s10863-010-9290-y.

schapira, A; Lang, A; Fahn, S; (2010) PREFACE. In: UNSPECIFIED

2009

Bhattacharyya, S; Schapira, AH; Mikhailidis, DP; Davar, J; (2009) Drug-induced fibrotic valvular heart disease. LANCET , 374 (9689) 577 - 585.

Cano, SJ; Riazi, A; Schapira, AHV; Cooper, JM; Hobart, JC; (2009) Friedreich's Ataxia Impact Scale: A New Measure Striving to Provide the Flexibility Required by Today's Studies. MOVEMENT DISORD , 24 (7) 984 - 992. 10.1002/mds.22420.

Chau, KY; Ching, HL; Schapira, AHV; Cooper, JM; (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J NEUROCHEM , 110 (3) 1005 - 1013. 10.1111/j.1471-4159.2009.06191.x.

Chau, KY; Korlipara, LVP; Cooper, JM; Schapira, AHV; (2009) Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J NEUROL SCI , 278 (1-2) 44 - 53. 10.1016/j.jns.2008.11.012.

Chaudhuri, KR; Martinez-Martin, P; Sherman, R; Naidu, Y; Odin, P; Sethi, K; Ondo, W; (2009) The Non Motor Staging of Parkinson's Disease: Results from an International Study. In: NEUROLOGY. (pp. A322 - A322). LIPPINCOTT WILLIAMS & WILKINS

Chaudhuri, KR; Schapira, AHV; (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. LANCET NEUROL , 8 (5) 464 - 474.

Gallagher, DA; Schapira, AHV; (2009) Etiopathogenesis and Treatment of Parkinson's Disease. CURR TOP MED CHEM , 9 (10) 860 - 868.

Gegg, ME; Cooper, JM; Schapira, AHV; Taanman, JW; (2009) Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells. PLOS ONE , 4 (3) , Article e4756. 10.1371/journal.pone.0004756. Green open access
file

Grunewald, A; Gegg, ME; Taanman, JW; King, RH; Kock, N; Klein, C; Schapira, AHV; (2009) Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. EXP NEUROL , 219 (1) 266 - 273. 10.1016/j.expneurol.2009.05.027.

Hartmann, A; Agid, Y; Schapira, AHV; (2009) What is Parkinson's Disease? From Pathophysiology to Symptoms. In: Parkinsonian Disorders in Clinical Practice. (pp. 1-39).

Martinez-Martin, P; Sherman, R; Naidu, Y; Richards, C; Odin, P; Stocchi, F; Macphee, G; (2009) Non- motor staging of Parkinson's disease (PD) and early longitudinal follow up results from an international study. In: MOVEMENT DISORDERS. (pp. S385 - S385). WILEY-LISS

Naidu, Y; Martinez-Martin, P; Mitra, T; Tluk, S; Stocchi, F; Macphee, G; Odin, P; (2009) Non declaration of non motor symptoms (NMS) of PD: An international study using the NMSQuest. In: MOVEMENT DISORDERS. (pp. S386 - S386). WILEY-LISS

Nissinen, H; Kuoppamaki, M; Leinonen, M; Schapira, AH; (2009) Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. EUR J NEUROL , 16 (12) 1305 - 1311. 10.1111/j.1468-1331.2009.02726.x.

Obeso, JA; Schapira, AH; (2009) Compensatory Mechanisms in Parkinson's Disease. MOVEMENT DISORD , 24 (1) 153 - 154. 10.1002/mds.22177.

Reddy, P; Naidu, Y; Suleyman, N; Tluk, S; Odin, P; Macphee, G; Stocchi, F; (2009) Characterisation of Restless Legs like syndrome in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S375 - S375). WILEY-LISS

Schapira, A; Hartmann, A; Agid, Y; (2009) Parkinsonian Disorders in Clinical Practice. [Book]. Wiley-Blackwell

Schapira, AH; Agid, Y; Barone, P; Jenner, P; Lemke, MR; Poewe, W; Rascol, O; (2009) Perspectives on recent advances in the understanding and treatment of Parkinson's disease. EUR J NEUROL , 16 (10) 1090 - 1099. 10.1111/j.1468-1331.2009.02793.x.

Schapira, AH; Olanow, CW; (2009) Initiating Therapy in Parkinson's Disease Reply. ANN NEUROL , 65 (4) 481 - 481. 10.1002/ana.21690.

Schapira, AHV; (2009) Disease modifying agents in Parkinson's disease? In: JOURNAL OF THE NEUROLOGICAL SCIENCES. (pp. S46 - S46). ELSEVIER SCIENCE BV

Schapira, AHV; (2009) Etiology and Pathogenesis of Parkinson Disease. NEUROL CLIN , 27 (3) 583 - +. 10.1016/j.ncl.2009.04.004.

Schapira, AHV; (2009) Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. NEUROLOGY , 72 S44 - S50.

Schapira, AHV; (2009) Neurobiology and treatment of Parkinson's disease. TRENDS PHARMACOL SCI , 30 (1) 41 - 47. 10.1016/j.tips.2008.10.005.

Schapira, AHV; Emre, M; Jenner, P; Poewe, W; (2009) Levodopa in the treatment of Parkinson's disease. EUR J NEUROL , 16 (9) 982 - 989. 10.1111/j.1468-1331.2009.02697.x.

Schapira, AHV; Hartmann, A; Agid, Y; (2009) Preface.

Schapira, AHV; Hartmann, A; Agid, Y; (2009) Treatment of Parkinson's Disease. In: Parkinsonian Disorders in Clinical Practice. (pp. 40-62).

Schapira, AHV; Samuels, MA; (2009) SERIES PREFACE. (Vol.33).

Taanman, JW; Daras, M; Albrecht, J; Davie, CA; Mallam, EA; Muddle, JR; Weatherall, M; (2009) Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). NEUROMUSCULAR DISORD , 19 (2) 151 - 154. 10.1016/j.nmd.2008.11.002.

Taanman, JW; Rahman, S; Pagnamenta, AT; Morris, AAM; Bitner-Glindzicz, M; Wolf, NI; Leonard, JV; (2009) Analysis of Mutant DNA Polymerase gamma in Patients With Mitochondrial DNA Depletion. HUM MUTAT , 30 (2) 248 - 254. 10.1002/humu.20852.

Tolosa, E; Chaudhuri, KR; Schapira, A; Poewe, W; (2009) Non-Motor Symptoms of Parkinson's Disease. [Book]. Oxford Univ Pr

Warner, TT; (2009) The genetics and pathogenesis of dystonia. In: Schapira, AHV and Lang, AE and Fahn, S, (eds.) Movement Disorders 4. (pp. 457-473). Elsevier: Philadelphia.

Webb, T; Mead, S; Beck, J; Uphill, J; Pal, S; Hampson, S; Wadsworth, JDF; (2009) Seven-year discordance in age at onset in monozygotic twins with inherited prion disease (P102L). NEUROPATH APPL NEURO , 35 (4) 427 - 432. 10.1111/j.1365-2990.2009.01012.x.

2008

Barone, P; Schapira, AHV; Debieuvre, CD; Massey, D; (2008) Design of a randomized, placebo-controlled trial of pramipexole in patients with Parkinson's disease and depressive symptoms. In: MOVEMENT DISORDERS. (pp. S199 - S199). WILEY-LISS

Bet, L; Bareggi, SR; Pacei, F; Bondiolotti, G; Meola, G; Schapira, AHV; (2008) Bimodal administration of entacapone in Parkinson's disease patients improves motor control. EUR J NEUROL , 15 (3) 268 - 273. 10.1111/j.1468-1331.2007.02043.x.

Cooper, JM; Korlipara, LVP; Hart, PE; Bradley, JL; Schapira, AHV; (2008) Coenzyme Q(10) and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q(10) therapy. EUR J NEUROL , 15 (12) 1371 - 1379. 10.1111/j.1468-1331.2008.02318.x.

DiFrancesco, JC; Cooper, JM; Lam, A; Hart, PE; Tremolizzo, L; Ferrarese, C; Schapira, AH; (2008) MELAS mitochondrial DNA mutation A3243G reduces glutamate transport in cybrids cell lines. EXP NEUROL , 212 (1) 152 - 156. 10.1016/j.expneurol.2008.03.015.

Grosset, DG; Schapira, AH; (2008) Timing the initiation of treatment in Parkinson's disease. J NEUROL NEUROSUR PS , 79 (6) 615 - 615. 10.1136/jnnp.2008.144741.

Healy, DG; Falchi, M; O'Sullivan, SS; Bonifati, V; Durr, A; Bressman, S; Brice, A; (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. LANCET NEUROL , 7 (7) 583 - 590. 10.1016/S1474-4422(08)70117-0. Gold open access

Healy, DG; Wood, NW; Schapira, AH; (2008) Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol , 8 (6) pp. 381-385. 10.1136/jnnp.2008.162420.

Lees, M; Roberts, G; Tabberer, M; DasGupta, R; Finnern, HW; Chaudhuri, R; Grossett, D; (2008) Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden. Current Medical Research and Opinion , 24 (10) pp. 2919-2930. 10.1185/03007990802344594.

Martinez, C; Finnern, HW; Rietbrock, S; Eaton, S; Chaudhuri, KR; Schapira, AHV; (2008) Patterns of treatment for restless legs syndrome in primary care in the united kingdom. CLIN THER , 30 (2) 405 - 418. 10.1016/j.clinthera.2008.02.001.

Olanow, CW; Kleburtz, K; Schapira, AHV; (2008) Why Have We Failed to Achieve Neuroprotection in Parkinson's Disease? ANN NEUROL , 64 (6) S101 - S110. 10.1002/ana.21461.

Rohrer, JD; Schapira, AH; (2008) Transient Horner's syndrome during lumbar epidural anaesthesia. EUR J NEUROL , 15 (5) 530 - 531. 10.1111/j.1468-1331.2008.02120.x.

Schapira, A; (2008) Mitochondrial DNA and disease. CONTINUUM Lifelong Learning in Neurology , 14 (2) pp. 133-148. 10.1212/01.CON.0000275629.24690.30.

Schapira, AH; (2008) Progress in Parkinson's disease. EUR J NEUROL , 15 (1) 1 - 1. 10.1111/j.1468-1331.2007.02036.x.

Schapira, AH; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: The impact of early vs. delayed treatment with prampiexole on new onset Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S194 - S194). WILEY-LISS

Schapira, AH; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S194 - S194). WILEY-LISS

Schapira, AHV; (2008) Mitochondrial Dysfunction in Neurodegenerative Diseases. NEUROCHEM RES , 33 (12) 2502 - 2509. 10.1007/s11064-008-9855-x.

Schapira, AHV; (2008) Controlling motor symptoms and fluctuations in adjunct therapy. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 418 - 418). BLACKWELL PUBLISHING

Schapira, AHV; (2008) Rasagiline in neurodegeneration. EXP NEUROL , 212 (2) 255 - 257. 10.1016/j.expneurol.2008.05.002.

Schapira, AHV; (2008) Progress in neuroprotection in Parkinson's disease. EUR J NEUROL , 15 5 - 13.

Schapira, AHV; (2008) The scientific and clinical basis for future therapies in Parkinson's disease - Foreword. EUR J NEUROL , 15 V - V.

Schapira, AHV; (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. MOVEMENT DISORD , 23 S515 - S520. 10.1002/mds.22146.

Schapira, AHV; (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. LANCET NEUROL , 7 (1) 97 - 109.

Schapira, AHV; Borgohain, R; Stocchi, F; Lorenzana, P; Onofrj, M; Lucini, V; Giuliani, R; (2008) Long-term safety and efficacy of safinamide added to dopamine agonists in early Parkinson's disease (PD). In: NEUROLOGY. (pp. A424 - A424). LIPPINCOTT WILLIAMS & WILKINS

Schapira, AHV; Hsu, HH; Scrine, K; Gordon, MF; Marek, KL; (2008) PROUD: the impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 132 - 132). BLACKWELL PUBLISHING

Schapira, AHV; Olanow, CW; (2008) Drug Selection and Timing of Initiation of Treatment in Early Parkinson's Disease. ANN NEUROL , 64 (6) S47 - S55. 10.1002/ana.21460.

Schapira, AHV; Samuels, MA; (2008) Series Preface. (Vol.32).

Schapira, AHV; Stocchi, F; Hunter, B; Giorgi, L; (2008) Adjunctive ropinirole 24-hour prolonged release compared with adjunctive ropinirole immediate release in patients with advanced PD: results from a per-protocol analysis of the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 131 - 132). BLACKWELL PUBLISHING

Schapira, AHV; Stocchi, F; Hunter, B; Giorgi, L; (2008) Comparison of adjunctive ropinirole 24-hour prolonged release and ropinirole immediate release in patients with advanced Parkinson's disease: A per-protocol analysis of the PREPARED study. In: MOVEMENT DISORDERS. (pp. S196 - S197). WILEY-LISS

Stocchi, F; Hunter, B; Giorgi, L; Schapira, AHV; (2008) Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinson's disease (PD): the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 134 - 134). BLACKWELL PUBLISHING

Stocchi, F; Hunter, B; Giorgi, L; Schapira, AHV; (2008) On evaluation of symptom control in patients with advanced PD receiving adjunctive ropinirole 24-hour prolonged release versus ropinirole immediate release: results from the PREPARED study. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 134 - 134). BLACKWELL PUBLISHING

Stocchi, F; Huter, B; Giorgi, L; Schapira, AHV; (2008) Comparison of adjunctive ropinirole 24-hour prolonged release and ropinirole immediate release in patients with advanced Parkinson's disease: The PREPARED study. In: MOVEMENT DISORDERS. (pp. S215 - S216). WILEY-LISS

Tan, EK; Schapira, AH; (2008) Hunting for genes in essential tremor. EUR J NEUROL , 15 (9) 889 - 890. 10.1111/j.1468-1331.2008.02226.x.

Tan, EK; Schapira, AH; (2008) Uniting Chinese across Asia: The LRRK2 Gly2385Arg risk variant. EUR J NEUROL , 15 (3) 203 - 204. 10.1111/j.1468-1331.2007.02053.x.

Yamamoto, M; Schapira, AH; (2008) Dopamine agonists in Parkinson's disease. Expert Rev Neurother , 8 (4) pp. 671-677. 10.1586/14737175.8.4.671.

2007

Schapira, AHV and Byrne, E and Dimauro, S and Frackowiak, RSJ and Johnson, RT and Mizuno, Y and Samuels, MA and Silberstein, SD and Wszolek, ZK (Eds). (2007) Neurology and clinical neuroscience - a textbook of neurology. [Book]. Elsevier: Philadelphia.

Anand, R; Onofrj, M; Schapira, AH; Rossetti, SM; (2007) Safinamide potentiates the effects of DA-agonists in early stage Parkinson's disease (PD) patients. In: MOVEMENT DISORDERS. (pp. S244 - S244). WILEY-LISS

Barone, P; Goetz, CG; Houben, J; Juergen, K; Leentjens, AFG; Poewe, W; Rascol, OO; (2007) PRODEST study: depressive symptoms in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S183 - S183). WILEY-LISS

Barone, P; Goetz, CG; Houben, JJ; Koester, J; Leentjens, AF; Poewe, W; Rascol, O; (2007) Prodest - Depressive symptoms in Parkinson's disease: Demographic data. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 61 - 61). BLACKWELL PUBLISHING

Barone, P; Goetz, CG; Houben, JJ; Koster, J; Leentjens, AFG; Powe, W; Rascol, O; (2007) PRODEST - Depressive symptoms in Parkinson's disease: Pattern across scales. PARKINSONISM RELAT D , 13 S51 - S51.

Chaudhuri, KR; Martinez-Martin, P; Brown, RG; Sethi, K; Stocchi, F; Odin, P; Ondo, W; (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. MOVEMENT DISORD , 22 (13) 1901 - 1911. 10.1002/mds.21596.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; Brown, RG; (2007) International validation of the first non-motor questionnaire (NMSQuest) and scale (NMSS) for Parkinson's disease. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 213 - 213). B M J PUBLISHING GROUP

Cooper, JM; Schapira, AHV; (2007) Friedreich's ataxia: Coenzyme Q(10) and vitamin E therapy. MITOCHONDRION , 7 S127 - S135. 10.1016/j.mito.2007.04.001.

Giladi, N; Boroojerdi, B; Korczyn, AD; Burn, DJ; Clarke, CE; Schapira, AH; SP513 Investigators, ; (2007) Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. MOVEMENT DISORD , 22 (16) 2398 - 2404. 10.1002/mds.21741.

Ginsberg, L; Daras, M; Davie, C; Albrecht, J; Schapira, AHV; Weatherall, M; Taanman, JW; (2007) A novel MNGIE mutation. In: EUROPEAN JOURNAL OF NEUROLOGY. (pp. 238 - 238). BLACKWELL PUBLISHING

Ginsberg, L; Schapiro, AHV; Taanman, JM; (2007) Relapsing neuropathy in an 18-year-old woman. LANCET NEUROL , 6 (2) 192 - 198.

Lynch, JM; Sisodiya, SM; (2007) Genetics of epilepsy. In: Schapira, AHV, (ed.) Neurology and clinical neuroscience. (pp. 681-689). Mosby/Elsevier: Philadelphia. Green open access
file

Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; MacPhee, G; Brown, RG; (2007) Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. MOVEMENT DISORD , 22 (11) 1623 - 1629. 10.1002/mds.21586.

Pienaar, I; Carr, J; Hattingh, S; Morten, K; Schallert, T; Schapira, AH; Daniels, W; (2007) A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. PARKINSONISM RELAT D , 13 S91 - S91.

Pienaar, I; Carr, J; Hattingh, S; Morten, K; Schallert, T; Schapira, AH; Daniels, W; (2007) A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. PARKINSONISM RELAT D , 13 S133 - S133.

Schapira, AH; (2007) Mitochondria in the etiology of Parkinson's disease. Handb Clin Neurol , 83 pp. 479-491. 10.1016/S0072-9752(07)83022-3.

Schapira, AHV; (2007) Chapter 11 Metabolic Causes of Ataxia. Blue Books of Neurology , 31 (C) pp. 255-267. 10.1016/S1877-184X(09)70085-1.

Schapira, AHV; (2007) Mitochondria in the etiology of Parkinson's disease. In: UNSPECIFIED

Schapira, AHV; (2007) Neurology and clinical neuroscience.

Schapira, AHV; (2007) Preface.

Schapira, AHV; (2007) Ropinirole 24-hour extended release for Parkinson's disease. In: AKTUELLE NEUROLOGIE. (pp. S15 - S17). GEORG THIEME VERLAG KG

Schapira, AHV; (2007) Treatment options in the modern management of Parkinson Disease. ARCH NEUROL-CHICAGO , 64 (8) 1083 - 1088.

Schapira, AHV; (2007) Mitochondrial dysfunction in Parkinson's disease. CELL DEATH DIFFER , 14 (7) 1261 - 1266. 10.1038/sj.cdd.4402160.

Schapira, AHV; (2007) Future directions in the treatment of Parkinson's disease. MOVEMENT DISORDERS , 22 S385 - S391. 10.1002/mds.21679.

Schapira, AHV; (2007) Metabolic causes of ataxia. In: Brice, A and Pulst, SM, (eds.) Spinocerebellar degenerations: the ataxias and spastic paraplegias. (pp. 255-267). Butterworth-Heinemann Elsevier: Philadelphia.

Schapira, AHV; (2007) Mitochondria in Movement Disorders. In: Jankovic, J and Tolosa, E, (eds.) Parkinson's Disease & Movement Disorders. (pp. 284-297). Lippincott Williams & Wilkins: Philadelphia.

Schapira, AHV; Chau, KY; Cooper, JM; (2007) Cabergoline protects against paraquant and alpha-synuclein mutation toxicity. In: NEUROLOGY. (pp. A110 - A110). LIPPINCOTT WILLIAMS & WILKINS

Schapira, AHV; Samuels, MA; (2007) Series Preface. (Vol.31).

Sharma, T; Stocchi, F; Schapira, AH; Borgohain, R; LoreDzana, P; Onoftj, M; Rossetti, S; (2007) Satinamide treatment improves cognition in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. XII - XIII). WILEY-LISS

Simonson, W; Hauser, RA; Schapira, AHV; (2007) Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. ANN PHARMACOTHER , 41 (11) 1842 - 1849. 10.1345/aph.1K348.

Turner, C; Cooper, JM; Schapira, AHV; (2007) Clinical correlates of mitochondrial function in Huntington's disease muscle. MOVEMENT DISORD , 22 (12) 1715 - 1721. 10.1002/mds.21540.

Warner, TT; (2007) Dystonia. In: Schapira, AHV, (ed.) Neurology and Clinical Neurosciences. (pp. 443-454). Mosby Elsevier: Philadelphia.

2006

Cano, SJ; Hobart, JC; Hart, PE; Kolipara, LVP; Schapira, AHV; Cooper, JM; (2006) International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia? In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 133 - 133). B M J PUBLISHING GROUP

Cano, SJ; Riazi, A; Cooper, JM; Schapira, AHV; Hobart, JC; (2006) The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 133 - 133). B M J PUBLISHING GROUP

Chaudhuri, KR; Healy, DG; Schapira, AHV; (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. LANCET NEUROL , 5 (3) 235 - 245.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Sethi, K; Ondo, W; Stocchi, F; Odin, P; (2006) International validation of the first united non motor symptoms scale for Parkinson's disease. Results from the first pilot NMSS study. In: NEUROLOGY. (pp. A124 - A124). LIPPINCOTT WILLIAMS & WILKINS

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Stocchi, F; Sethi, K; Odin, P; Brown, RG; (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. MOVEMENT DISORD , 21 (7) 916 - 923. 10.1002/mds.20844.

Iravani, MM; Haddon, CO; Cooper, JM; Jenner, P; Schapira, AH; (2006) Pramipexole protects against MPTP toxicity in non-human primates. J NEUROCHEM , 96 (5) 1315 - 1321. 10.1111/j.1471-4159.2005.03625.x.

Lodi, R; Tonon, C; Calabrese, V; Schapira, AHV; (2006) Friedreich's ataxia: From disease mechanisms to therapeutic interventions. ANTIOXID REDOX SIGN , 8 (3-4) 438 - 443.

Naidu, Y; Schapira, AH; Martinez-Martin, P; Sethi, K; Odin, P; Stocchi, F; Ondo, W; (2006) International validation study of the first comprehensive unified Nonmotor Symptoms Scale (NMSS) for Parkinson's disease (PD). In: MOVEMENT DISORDERS. (pp. S613 - S613). WILEY-LISS

Olanow, CW; Schapira, AHV; LeWitt, PA; Kieburtz, K; Sauer, D; Olivieri, G; Pohlmann, H; (2006) TCH346 as a neuroprotective drug in Parkinson"s disease: a double-blind, randomised, controlled trial. LANCET NEUROL , 5 (12) 1013 - 1020. 10.1016/S1474-4422(06)70602-0.

Riazi, A; Cano, SJ; Cooper, JM; Bradley, JL; Schapira, AHV; Hobart, JC; (2006) Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes? MOVEMENT DISORD , 21 (9) 1396 - 1403. 10.1002/mds.20985.

Schapira, A.H.V.; Cleeter, M.W.J.; Muddle, J.R.; Workman, J.M.; Cooper, J.M.; King, R.H.M.; (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Annals of Neurology , 60 (2) pp. 253-255. 10.1002/ana.20934.

Schapira, AH; (2006) Scientific basis for neuroprotection in Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S14 - S14). WILEY-LISS

Schapira, AH; (2006) The use of rasagiline in Parkinson's disease. journal of neural transmission , 71 pp. 1-5.

Schapira, AHV; (2006) Parkinson's disease. In: Schapira, AHV, (ed.) Neurology and clinical neuroscience. (pp. 927-960). Mosby/Elsevier: Philadelphia.

Schapira, AHV; (2006) Sudden onset of sleep and daytime drowsiness in Parkinson's disease. In: JOURNAL OF THE NEUROLOGICAL SCIENCES. (pp. 319 - 319). ELSEVIER SCIENCE BV

Schapira, AHV; (2006) European Journal of Neurology: Preface. European Journal of Neurology , 13 (SUPPL. 2) 1-. 10.1111/j.1468-1331.2006.01584.x.

Schapira, AHV; (2006) RLS patients: who are they? EUR J NEUROL , 13 2 - 7.

Schapira, AHV; (2006) Restless Legs Syndrome - Preface. EUR J NEUROL , 13 1 - 1.

Schapira, AHV; (2006) Improving the management of Parkinson's disease: New ropinirole data from EASE-PD in context. EUR J NEUROL , 13 317 - 317.

Schapira, AHV; (2006) Non-motor symptoms. EUR J NEUROL , 13 316 - 317.

Schapira, AHV; (2006) The importance of LRRK2 mutations in Parkinson disease. ARCH NEUROL-CHICAGO , 63 (9) 1225 - 1228.

Schapira, AHV; (2006) Mitochondrial disease. LANCET , 368 (9529) 70 - 82.

Schapira, AHV; (2006) Mitochondria in neurodegeneratives diseases. In: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. (pp. S82 - S83). CAMBRIDGE UNIV PRESS

Schapira, AHV; (2006) Etiology of Parkinson's disease. NEUROLOGY , 66 (10) S10 - S23.

Schapira, AHV; (2006) Etiology of Parkinson's disease. Neurology , 66 (10 SUPPL)

Schapira, AHV; (2006) The use of rasagiline in Parkinson's disease. J NEURAL TRANSM-SUPP (71) 157 - 161.

Schapira, AHV; Bezard, E; Brotchie, J; Calon, F; Collingridge, GL; Ferger, B; Hengerer, B; (2006) Novel pharmacological targets for the treatment of Parkinson's disease. NAT REV DRUG DISCOV , 5 (10) 845 - 854. 10.1038/nrd2087.

Schapira, AHV; Cleeter, MWJ; Muddle, JR; Workman, JM; Cooper, JM; King, RHM; (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. ANN NEUROL , 60 (2) 253 - 255. 10.1002/ana.20934.

Schapira, AHV; Muddle, JR; Workman, JM; Cleeter, MWJ; Cooper, MJ; King, RHM; (2006) Systemic proteasomal inhibition causes loss of nigral TH positive neurons. In: NEUROLOGY. (pp. A146 - A146). LIPPINCOTT WILLIAMS & WILKINS

Schapira, AHV; Obeso, J; (2006) Timing of treatment initiation in Parkinson's disease: A need for reappraisal? ANN NEUROL , 59 (3) 559 - 562.

Schapira, AHV; Obeso, JA; (2006) Treatment should not be initiated too soon in Parkinson's disease - Reply. ANN NEUROL , 59 (3) 564 - 565.

Stacy, M; Hauser, R; Oertel, W; Schapira, A; Sethi, K; Stocchi, F; Tolosa, E; (2006) End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol , 29 (6) pp. 312-321. 10.1097/01.WNF.0000232277.68501.08.

Stacy, M; Hauser, R; Oertel, W; Schapira, A; Sethi, K; Stocchi, T; Tolosa, E; (2006) End-of-dose wearing off in Parkinson disease: A 9-question survey assessment. CLINICAL NEUROPHARMACOLOGY , 29 (6) pp. 312-321. 10.1097/01.WNF.0000232277.

Tsuboi, Y; Yamada, T; Chaudhuri, RK; Martinez-Martin, P; Schapira, AH; P International, ; (2006) Comparison of profile of non motor symptoms in Japanese patients with PD with Euoprean patients and healthy controls. Extension of the NMSQuest study. In: MOVEMENT DISORDERS. (pp. S648 - S649). WILEY-LISS

2005

Baracca, A; Solaini, G; Sgarbi, G; Lenaz, G; Baruzzi, A; Schapira, AHV; Martinuzzi, A; (2005) Severe impairment of complex I-Driven adenosine triphosphate synthesis in Leber hereditary optic neuropathy cybrids. ARCH NEUROL-CHICAGO , 62 (5) 730 - 736.

Cano, SJ; Hobart, JC; Hart, PE; Korlipara, LVP; Schapira, AH; Cooper, JM; (2005) International Cooperative Ataxia Rating Scale (ICARS): Appropriate for studies of Friedreich's ataxia? MOVEMENT DISORD , 20 (12) 1585 - 1591. 10.1002/mds.20651.

Chaudhuri, KR; Martinez-Martin, P; Schapira, AHV; Ondo, W; Sethi, K; PD NMS Scale Dev Grp, ; (2005) An international multicentre study validating the first screening questionnaire (NMS-quest) for comprehensive assessment of non motor symptoms of Parkinson's disease. In: MOVEMENT DISORDERS. (pp. S50 - S50). WILEY-LISS

Danielson, SR; Carelli, V; Tan, GL; Martinuzzi, A; Schapira, AHV; Savontaus, ML; Cortopassi, GA; (2005) Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. BRAIN , 128 1026 - 1037. 10.1093/brain/awh447.

Davie, CA; Schapira, AHV; (2005) First-line treatment in Parkinson's disease. Practical Neurology , 5 (3) pp. 160-167. 10.1111/j.1474-7766.2005.00303.x.

Gu, M; Iravani, MM; Cooper, JM; King, D; Jenner, P; Schapira, AHV; (2005) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms (vol 91, pg 1075, 2004). J NEUROCHEM , 92 (1) 215 - 215. 10.1111/j.1471-4159.2004.02966.x.

Hart, PE; Lodi, R; Rajagopalan, B; Bradley, JL; Crilley, JG; Turner, C; Blamire, AM; (2005) Antioxidant treatment of patients with Friedreich ataxia - Four-year follow-up. ARCH NEUROL-CHICAGO , 62 (4) 621 - 626.

Lo, S; Tolner, B; Taanman, JW; Cooper, JM; Gu, M; Hartley, JA; Schapira, AHV; (2005) Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. INT J ONCOL , 27 (2) 337 - 344.

Olanow, CW; Schapira, AHV; (2005) Surgical approaches to the treatment of parkinson's disease. In: Principles of Treatment in Parkinson's Disease. (pp. 217-234).

Schapira, A; Bate, G; Kirkpatrick, P; (2005) Rasagiline. NATURE REVIEWS DRUG DISCOVERY , 4 (8) pp. 625-626. 10.1038/nrd1803.

Schapira, A; Olanow, CW; (2005) Principles Of Treatment In Parkinson's Disease.

Schapira, AH; (2005) Rasagiline, a novel second generation MAO-B inhibitor - pharmacological profile. EUR J NEUROL , 12 329 - 329.

Schapira, AH; (2005) Mitochondrial DNA and disease: what happens when things go wrong? The Biochemist , 27 (3) pp. 24-27.

Schapira, AHV; (2005) Present and future drug treatment for Parkinson's disease. J NEUROL NEUROSUR PS , 76 (11) 1472 - 1478. 10.1136/jnnp.2004.035980. Gold open access

Schapira, AHV; (2005) Disorders of the mitochondrial respiratory chain. In: Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics. (pp. 909-926).

Schapira, AHV; Olanow, CW; (2005) Preface.

Schapira, AHV; Olanow, CW; (2005) The medical management of parkinson's disease. In: Principles of Treatment in Parkinson's Disease. (pp. 119-143).

Strand, AD; Aragaki, AK; Shaw, D; Bird, T; Holton, J; Turner, C; Tapscott, SJ; (2005) Gene expression in Huntington's disease skeletal muscle: a potential biomarker. HUM MOL GENET , 14 (13) 1863 - 1876. 10.1093/hmg/ddi192.

Taanman, JW; Schapira, AHV; (2005) Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. NEUROSCI LETT , 376 (1) 56 - 59. 10.1016/j.neulet.2004.11.023.

Tabrizi, SJ; Blamire, AM; Manners, DN; Rajagopalan, B; Styles, P; Schapira, AHV; Warner, TT; (2005) High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. NEUROLOGY , 64 (9) 1655 - 1656.

Wiklund, L; Fiskum, G; Chuang, DM; Slikker, W; Xi, X; Banik, N; Lazarovici, P; (2005) Questions and answers: Session V: Neuroprotective approaches and models. In: (pp. pp. 233-236).

2004

Asbury, AK; Schapira, AHV; (2004) Series Preface. (Vol.29).

Beretta, S; Mattavelli, L; Sala, G; Tremolizzo, L; Schapira, AHV; Martinuzzi, A; Carelli, V; (2004) Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. BRAIN , 127 2183 - 2192. 10.1093/brain/awh258.

Bradley, J.L.; Homayoun, S.; Hart, P.E.; Schapira, A.H.V.; Cooper, J.M.; (2004) Role of oxidative damage in Friedreich's Ataxia. Neurochemical Research , 29 (3) pp. 561-567. 10.1023/B:NERE.0000014826.00881.c3.

Bradley, JL; Homayoun, S; Hart, PE; Schapira, AHV; Cooper, JM; (2004) Role of oxidative damage in Friedreich's ataxia. NEUROCHEM RES , 29 (3) 561 - 567.

Chaudhuri, K; Schapira, AH; Martinez-Martin, P; Brown, K; (2004) On behalf of the International Parkinson's Disese Non-Motor Symptom Scale Development Group. Can we improve the holistic assessment of Parkinson's disease? The development of a non-motor symptom questionnaire adn scale for PD:. Advances in Clinical Neuroscience and Rehabilitation , 4 pp. 20-21.

Chaudhuri, KR; Forbes, A; Grosset, D; Lees, A; Shneerson, J; Schapira, A; Stillman, P; (2004) Diagnosing restless legs syndrome (RLS) in primary care. CURR MED RES OPIN , 20 (11) 1785 - 1795. 10.1185/030079904X5472.

Chaudhuri, KR; Schapira, AHV; Martinez-Martin, P; Sethi, K; MacPhee, G; Brown, R; Odin, P; (2004) Development and pilot study of the first nonmotor symptom screening questionnaire and scale for Parkinson's disease using an international multidisciplinary approach. In: MOVEMENT DISORDERS. (pp. 1120 - 1120). WILEY-LISS

Davie, CA; Schapira, AH; (2004) Use of COMT inhibitors in the treatment of Parkinson's disease. Clinical Geriatrics , 12 (6) pp. 19-24.

Francis, J; Cooke, F; Bradley, JL; Blamire, AM; Schapira, AHV; Neubauer, S; Cooper, JM; (2004) Myocardial. hypertrophy in Friedreich's ataxia (FA) is a function of duration of the disease and the length of the GAA trinucleotide repeat; A cross sectional MRI study. In: HEART. (pp. A58 - A58). B M J PUBLISHING GROUP

Gu, M; Irvani, M; Cooper, JM; King, D; Jenner, P; Schapira, AHV; (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J NEUROCHEM , 91 (5) 1075 - 1081. 10.1111/j.1471-4159.2004.02804.x.

Korlipara, LVP; Cooper, JM; Schapira, AHV; (2004) Oxidative stress in a neuronal model of alpha synuclein overexpression. In: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. (pp. 1226 - 1226). B M J PUBLISHING GROUP

Korlipara, LVP; Cooper, JM; Schapira, AHV; (2004) Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. NEUROPHARMACOLOGY , 46 (4) 562 - 569. 10.1016/j.neuropharm.2003.10.015.

MacMahon, D; Koller, W; Martinex-Martin, P; Chaudhuri, K; Schapira, A; Sethi, K; Brown, R; (2004) Can we improve the holistic assessment of Parkinson's disease? The development of a non-motor symptom questionnaire and scale for Parkinson's disease. Advances in Clinical Opinions , 20 pp. 1785-1795.

McCabe, DJH; Turner, NC; Chao, D; Leff, A; Gregson, NA; Womersley, HJ; Mak, I; (2004) Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. NEUROLOGY , 62 (8) 1402 - 1404.

Olanow, CW; Schapira, AHV; (2004) Measuring the effects of therapy in Parkinson disease - Reply. JAMA-J AM MED ASSOC , 291 (20) 2431 - 2431.

Orth, M; Tabrizi, SJ; Tomlinson, C; Messmer, K; Korlipara, LVP; Scapira, AHV; Cooper, JM; (2004) G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. NEUROCHEM INT , 45 (5) 669 - 676. 10.1016/j.neuint.2004.03.029.

Page, RA; Davie, CA; MacManus, D; Miszkiel, KA; Walshe, JM; Miller, DH; Lees, AJ; (2004) Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. NEUROLOGY , 63 (4) 638 - 643.

Rafique, R; Schapira, AHV; Cooper, JM; (2004) Mitochondrial respiratory chain dysfunction in ageing; Influence of vitamin E deficiency. FREE RADICAL RES , 38 (2) 157 - 165. 10.1080/10715760310001643311.

Samii, A; Nutt, JG; Ransom, BR; (2004)